In colorectal cancer the combination of the BRAF inhibitor encorafenib with the EGFR monoclonal antibody cetuximab has shown promising results and was approved for the treatment of patients with BRAF V600E mutations (Tabernero et al., 2021). This evidence concerns the gene BRAF and colorectal cancer.